<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00289900</url>
  </required_header>
  <id_info>
    <org_study_id>0524B-024</org_study_id>
    <secondary_id>MK-0524B-024</secondary_id>
    <secondary_id>2005_103</secondary_id>
    <nct_id>NCT00289900</nct_id>
  </id_info>
  <brief_title>Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK0524B Versus Atorvastatin in Patients With Mixed Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This is a 12-week clinical trial in participants with mixed hyperlipidemia to study the
      effects of MK-0524B on lipids.The primary hypothesis is that MK-0524B (dosed as MK-0524A
      coadministered with simvastatin) will be superior to atorvastatin on decreasing the low
      denisity lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) ratio
      for the following dose comparisons: 2g/20 mg MK-0524B versus 10 mg atorvastatin, 2g/40 mg
      MK-0524B versus 20 mg atorvastatin, 2g/40 mg MK-0524B versus 40 mg atorvastatin, and 2g/40 mg
      MK-0524B versus 80 mg atorvastatin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline in the LDL-C/HDL-C Ratio</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the LDL-C and HDL-C levels. The LDL-C/HDL-C ratio was then calculated for baseline and Week 12 and the change from baseline at Week 12 was recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in HDL-C</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the HDL-C levels. The change from baseline at Week 12 was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Triglycerides (TG)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the TG levels. The change from baseline at Week 12 was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Non-HDL-C</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the non-HDL-C levels. The change from baseline at Week 12 was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in LDL-C</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the LDL-C levels. The change from baseline at Week 12 was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Apolipoprotein (Apo) B</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the Apo B levels. The change from baseline at Week 12 was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Apo A-I</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the Apo A-I levels. The change from baseline at Week 12 was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Total Cholesterol (TC)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the TC levels. The change from baseline at Week 12 was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Lipoprotein (a) (Lp[a])</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the Lp(a) levels. The change from baseline at Week 12 was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in C-reactive Protein (CRP)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the CRP levels. The change from baseline at Week 12 was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in TC/HDL-C Ratio</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the TC and HDL-C levels. The TC/HDL-C ratio was then calculated for baseline and Week 12 and the change from baseline at Week 12 was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of &gt;=3 x Upper Limit of Normal (ULN)</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of either AST or ALT that were 3 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Elevations in ALT and/or AST of &gt;=5 x ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of either AST or ALT that was 5 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Elevations in ALT and/or AST of &gt;=10 x ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of either AST or ALT that was 10 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Creatine Kinase (CK) &gt;=10 x ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had CK assessed throughout the 12 week treatment period. Participants who had any CK level that was &gt;=10 x ULN were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CK &gt;=10 x ULN With Muscle Symptoms</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had CK assessed throughout the 24 week treatment period. Participants who had any CK level that was &gt;=10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CK &gt;=10 x ULN With Muscle Symptoms - Drug Related</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had CK assessed throughout the 12 week treatment period. Participants who had any CK level that was &gt;=10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly related to study drug were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New Diagnosis of Impaired Fasting Blood Glucose</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had blood glucose levels assessed throughout the 12 week treatment period. Participants who had the new diagnosis of impaired fasting blood glucose were recorded. A pre-defined set of MedDRA terms was used to identify participants whose glycemic status became 'impaired' during the course of treatment (from clinical adverse experience reports). The MedDRA terms were as follows: blood glucose increased, blood glucose abnormal, glucose tolerance decreased, glucose tolerance test abnormal, carbohydrate tolerance decreased, glucose tolerance impaired, hyperglycaemia, impaired fasting glucose, impaired insulin secretion, metabolic syndrome, insulin resistance, insulin resistance syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New Diagnosis of Diabetes</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had blood glucose levels assessed throughout the 12 week treatment period. Participants who with newly diagnosed of diabetes were recorded. A participant was classified as having new onset diabetes if they experienced an adverse Event (AE) related to a diagnosis of diabetes (based on a pre-defined set of Medical Dictionary for Regulatory Activities [MedDRA] terms), or if they started taking an anti-diabetic medication during the course of the study. The MedDRA terms were as follows: diabetes mellitus, diabetes mellitus insulin-dependent, diabetes mellitus non-insulin dependent, insulin-requiring type II diabetes mellitus, insulin resistant diabetes, diabetes with hyperosmolarity, latent autoimmune diabetes in adults.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Confirmed Adjudicated Cardiovascular Event</measure>
    <time_frame>up to 14 weeks</time_frame>
    <description>Select serious adverse cardiovascular events and all-cause mortality that occurred during the treatment phase of the study were adjudicated by an expert committee external to the sponsor. Those events confirmed by the committee a cardiovascular events were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience at Least 1 Clinical Adverse Event (AE)</measure>
    <time_frame>up to 14 weeks</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience at Least 1 Laboratory Adverse Event (AE)</measure>
    <time_frame>up to 14 weeks</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Discontinued From the Study Due to a Clinical AE</measure>
    <time_frame>up to 14 weeks</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant. Participants who were discontinued from the study due to a clinical AE were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Discontinued From the Study Due to a Laboratory AE</measure>
    <time_frame>up to 14 weeks</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. Participants who were discontinued from the study due to a laboratory AE were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience at Least 1 Hepatitis-related Clinical AE</measure>
    <time_frame>up to 14 weeks</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Hepatitis-related AEs were identified by a collective review using the following pre-specified set of preferred terms: cholestasis, hepatic necrosis, hepatocellular damage, cytolytic hepatitis, hepatitis, hepatomegaly, jaundice, hepatic failure, hepatitis cholestatic, jaundice cholestatic, hepatitis fulminant, hyperbilirubinaemia, jaundice hepatocellular, ocular icterus, yellow skin, hepatic function abnormal, acute hepatic failure, subacute hepatic failure, hepatitis acute, hepatitis toxic, hepatotoxicity, and mixed hepatocellular-cholestatic injury.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">2340</enrollment>
  <condition>Mixed Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>MK-0524B 2g/20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0524B 2g/40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0524A</intervention_name>
    <arm_group_label>MK-0524B 2g/20 mg</arm_group_label>
    <arm_group_label>MK-0524B 2g/40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <arm_group_label>MK-0524B 2g/20 mg</arm_group_label>
    <arm_group_label>MK-0524B 2g/40mg</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant 18 to 80 years of age with Mixed Hyperlipidemia with LDL-C between 130 and
             190 mg/dL and Triglycerides between 150 and 500 mg/dL

        Exclusion Criteria:

          -  Pregnant or lactating women, or women intending to become pregnant

          -  Diabetes mellitus that is poorly controlled, newly diagnosed, or taking new or
             recently adjusted antidiabetic therapy (with the exception of Â± 10 units of insulin)

          -  Human immunodeficiency virus (HIV) positive

          -  Any of the following within the past 3 months: heart attack, stoke, heart bypass
             surgery, unstable angina, angioplasty

          -  Active or chronic liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Finland</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Lithuania</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Chen F, Maccubbin D, Yan L, Sirah W, Chen E, Sisk CM, Davidson M, Blomqvist P, McKenney JM. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol. 2013 Jul 15;167(1):225-31. doi: 10.1016/j.ijcard.2011.12.103. Epub 2012 Feb 4.</citation>
    <PMID>22305632</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2006</study_first_submitted>
  <study_first_submitted_qc>February 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2006</study_first_posted>
  <results_first_submitted>December 17, 2015</results_first_submitted>
  <results_first_submitted_qc>December 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2016</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type V</mesh_term>
    <mesh_term>Lipidoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis Link</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=0524B-024&amp;kw=0524B-024&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MK-0524B 2g/20 mg</title>
          <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>MK-0524B 2g/40mg</title>
          <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Atorvastatin 10 mg</title>
          <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Atorvastatin 20 mg</title>
          <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
        </group>
        <group group_id="P5">
          <title>Atorvastatin 40 mg</title>
          <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
        </group>
        <group group_id="P6">
          <title>Atorvastatin 80 mg</title>
          <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="436"/>
                <participants group_id="P3" count="298"/>
                <participants group_id="P4" count="439"/>
                <participants group_id="P5" count="437"/>
                <participants group_id="P6" count="433"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="435"/>
                <participants group_id="P3" count="298"/>
                <participants group_id="P4" count="439"/>
                <participants group_id="P5" count="437"/>
                <participants group_id="P6" count="433"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="316"/>
                <participants group_id="P3" count="265"/>
                <participants group_id="P4" count="380"/>
                <participants group_id="P5" count="392"/>
                <participants group_id="P6" count="372"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="120"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="59"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="61"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant had flushing</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>site terminated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-0524B 2g/20 mg</title>
          <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>MK-0524B 2g/40mg</title>
          <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Atorvastatin 10 mg</title>
          <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Atorvastatin 20 mg</title>
          <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Atorvastatin 40 mg</title>
          <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
        </group>
        <group group_id="B6">
          <title>Atorvastatin 80 mg</title>
          <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="297"/>
            <count group_id="B2" value="436"/>
            <count group_id="B3" value="298"/>
            <count group_id="B4" value="439"/>
            <count group_id="B5" value="437"/>
            <count group_id="B6" value="433"/>
            <count group_id="B7" value="2340"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="10.8"/>
                    <measurement group_id="B2" value="55.0" spread="10.3"/>
                    <measurement group_id="B3" value="53.7" spread="10.6"/>
                    <measurement group_id="B4" value="54.8" spread="10.8"/>
                    <measurement group_id="B5" value="55.1" spread="10.1"/>
                    <measurement group_id="B6" value="54.7" spread="10.5"/>
                    <measurement group_id="B7" value="54.7" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="237"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="248"/>
                    <measurement group_id="B5" value="232"/>
                    <measurement group_id="B6" value="258"/>
                    <measurement group_id="B7" value="1309"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="191"/>
                    <measurement group_id="B5" value="205"/>
                    <measurement group_id="B6" value="175"/>
                    <measurement group_id="B7" value="1031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline in the LDL-C/HDL-C Ratio</title>
        <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the LDL-C and HDL-C levels. The LDL-C/HDL-C ratio was then calculated for baseline and Week 12 and the change from baseline at Week 12 was recorded.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg</title>
            <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0524B 2g/40mg</title>
            <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin 40 mg</title>
            <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>Atorvastatin 80 mg</title>
            <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in the LDL-C/HDL-C Ratio</title>
          <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the LDL-C and HDL-C levels. The LDL-C/HDL-C ratio was then calculated for baseline and Week 12 and the change from baseline at Week 12 was recorded.</description>
          <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="361"/>
                <count group_id="O3" value="280"/>
                <count group_id="O4" value="402"/>
                <count group_id="O5" value="410"/>
                <count group_id="O6" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.9" lower_limit="-53.8" upper_limit="-47.9"/>
                    <measurement group_id="O2" value="-53.0" lower_limit="-55.4" upper_limit="-50.7"/>
                    <measurement group_id="O3" value="-37.6" lower_limit="-40.5" upper_limit="-34.8"/>
                    <measurement group_id="O4" value="-42.4" lower_limit="-44.5" upper_limit="-40.0"/>
                    <measurement group_id="O5" value="-47.9" lower_limit="-50.1" upper_limit="-45.7"/>
                    <measurement group_id="O6" value="-48.8" lower_limit="-51.1" upper_limit="-46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-13.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.8</ci_lower_limit>
            <ci_upper_limit>-9.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-10.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>-7.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>-2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in HDL-C</title>
        <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the HDL-C levels. The change from baseline at Week 12 was recorded.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg</title>
            <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0524B 2g/40mg</title>
            <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin 40 mg</title>
            <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>Atorvastatin 80 mg</title>
            <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in HDL-C</title>
          <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the HDL-C levels. The change from baseline at Week 12 was recorded.</description>
          <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="361"/>
                <count group_id="O3" value="280"/>
                <count group_id="O4" value="402"/>
                <count group_id="O5" value="410"/>
                <count group_id="O6" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" lower_limit="24.7" upper_limit="29.1"/>
                    <measurement group_id="O2" value="26.6" lower_limit="24.8" upper_limit="28.4"/>
                    <measurement group_id="O3" value="7.0" lower_limit="4.8" upper_limit="9.1"/>
                    <measurement group_id="O4" value="5.3" lower_limit="3.6" upper_limit="7.0"/>
                    <measurement group_id="O5" value="4.5" lower_limit="2.8" upper_limit="6.2"/>
                    <measurement group_id="O6" value="3.6" lower_limit="1.9" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>19.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.2</ci_lower_limit>
            <ci_upper_limit>22.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>21.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.0</ci_lower_limit>
            <ci_upper_limit>23.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>22.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.8</ci_lower_limit>
            <ci_upper_limit>24.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>23.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.7</ci_lower_limit>
            <ci_upper_limit>25.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Triglycerides (TG)</title>
        <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the TG levels. The change from baseline at Week 12 was recorded.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg</title>
            <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0524B 2g/40mg</title>
            <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin 40 mg</title>
            <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>Atorvastatin 80 mg</title>
            <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Triglycerides (TG)</title>
          <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the TG levels. The change from baseline at Week 12 was recorded.</description>
          <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
          <units>Percentage change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="361"/>
                <count group_id="O3" value="280"/>
                <count group_id="O4" value="402"/>
                <count group_id="O5" value="410"/>
                <count group_id="O6" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.3" lower_limit="-44.2" upper_limit="-36.5"/>
                    <measurement group_id="O2" value="-42.0" lower_limit="-45.7" upper_limit="-38.4"/>
                    <measurement group_id="O3" value="-21.9" lower_limit="-25.0" upper_limit="-18.8"/>
                    <measurement group_id="O4" value="-23.8" lower_limit="-26.5" upper_limit="-21.2"/>
                    <measurement group_id="O5" value="-30.4" lower_limit="-32.8" upper_limit="-27.9"/>
                    <measurement group_id="O6" value="-33.8" lower_limit="-36.4" upper_limit="-31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-17.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.2</ci_lower_limit>
            <ci_upper_limit>-13.3</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate of the difference between treatments with a corresponding distribution-free confidence interval (CI) based on Wilcoxonâs rank sum test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-15.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.1</ci_lower_limit>
            <ci_upper_limit>-11.9</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate of the difference between treatments with a corresponding distribution-free CI based on Wilcoxonâs rank sum test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-10.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.7</ci_lower_limit>
            <ci_upper_limit>-7.0</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate of the difference between treatments with a corresponding distribution-free CI based on Wilcoxonâs rank sum test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>-3.4</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate of the difference between treatments with a corresponding distribution-free CI based on Wilcoxonâs rank sum test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Non-HDL-C</title>
        <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the non-HDL-C levels. The change from baseline at Week 12 was recorded.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg</title>
            <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0524B 2g/40mg</title>
            <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin 40 mg</title>
            <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>Atorvastatin 80 mg</title>
            <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Non-HDL-C</title>
          <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the non-HDL-C levels. The change from baseline at Week 12 was recorded.</description>
          <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="361"/>
                <count group_id="O3" value="280"/>
                <count group_id="O4" value="402"/>
                <count group_id="O5" value="410"/>
                <count group_id="O6" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.4" lower_limit="-42.9" upper_limit="-37.9"/>
                    <measurement group_id="O2" value="-42.2" lower_limit="-44.2" upper_limit="-40.2"/>
                    <measurement group_id="O3" value="-31.3" lower_limit="-33.7" upper_limit="-28.9"/>
                    <measurement group_id="O4" value="-36.8" lower_limit="-38.7" upper_limit="-34.9"/>
                    <measurement group_id="O5" value="-42.6" lower_limit="-44.5" upper_limit="-40.7"/>
                    <measurement group_id="O6" value="-44.6" lower_limit="-46.6" upper_limit="-42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-9.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>-6.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-5.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>-2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.771</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in LDL-C</title>
        <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the LDL-C levels. The change from baseline at Week 12 was recorded.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg</title>
            <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0524B 2g/40mg</title>
            <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin 40 mg</title>
            <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>Atorvastatin 80 mg</title>
            <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in LDL-C</title>
          <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the LDL-C levels. The change from baseline at Week 12 was recorded.</description>
          <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="361"/>
                <count group_id="O3" value="280"/>
                <count group_id="O4" value="402"/>
                <count group_id="O5" value="410"/>
                <count group_id="O6" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.4" lower_limit="-43.0" upper_limit="-37.7"/>
                    <measurement group_id="O2" value="-42.8" lower_limit="-44.9" upper_limit="-40.7"/>
                    <measurement group_id="O3" value="-33.6" lower_limit="-36.1" upper_limit="-31.0"/>
                    <measurement group_id="O4" value="-39.8" lower_limit="-41.8" upper_limit="-37.8"/>
                    <measurement group_id="O5" value="-45.6" lower_limit="-47.6" upper_limit="-43.6"/>
                    <measurement group_id="O6" value="-47.5" lower_limit="-49.5" upper_limit="-45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in least Squares Mean</param_type>
            <param_value>-6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>-3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Sqaures Mean</param_type>
            <param_value>4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>7.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Apolipoprotein (Apo) B</title>
        <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the Apo B levels. The change from baseline at Week 12 was recorded.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg</title>
            <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0524B 2g/40mg</title>
            <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin 40 mg</title>
            <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>Atorvastatin 80 mg</title>
            <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Apolipoprotein (Apo) B</title>
          <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the Apo B levels. The change from baseline at Week 12 was recorded.</description>
          <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="272"/>
                <count group_id="O4" value="396"/>
                <count group_id="O5" value="404"/>
                <count group_id="O6" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.1" lower_limit="-38.4" upper_limit="-33.7"/>
                    <measurement group_id="O2" value="-38.0" lower_limit="-39.9" upper_limit="-36.2"/>
                    <measurement group_id="O3" value="-26.9" lower_limit="-29.2" upper_limit="-24.6"/>
                    <measurement group_id="O4" value="-32.8" lower_limit="-34.6" upper_limit="-31.0"/>
                    <measurement group_id="O5" value="-37.2" lower_limit="-38.9" upper_limit="-35.4"/>
                    <measurement group_id="O6" value="-38.3" lower_limit="-40.1" upper_limit="-36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-9.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>-6.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>-2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.476</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.845</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Apo A-I</title>
        <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the Apo A-I levels. The change from baseline at Week 12 was recorded.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg</title>
            <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0524B 2g/40mg</title>
            <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin 40 mg</title>
            <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>Atorvastatin 80 mg</title>
            <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Apo A-I</title>
          <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the Apo A-I levels. The change from baseline at Week 12 was recorded.</description>
          <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="272"/>
                <count group_id="O4" value="396"/>
                <count group_id="O5" value="404"/>
                <count group_id="O6" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="8.7" upper_limit="12.6"/>
                    <measurement group_id="O2" value="8.2" lower_limit="6.7" upper_limit="9.7"/>
                    <measurement group_id="O3" value="1.7" lower_limit="-0.2" upper_limit="3.5"/>
                    <measurement group_id="O4" value="0.4" lower_limit="-1.0" upper_limit="1.9"/>
                    <measurement group_id="O5" value="-0.8" lower_limit="-2.2" upper_limit="0.7"/>
                    <measurement group_id="O6" value="-2.5" lower_limit="-3.9" upper_limit="-1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>9.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.6</ci_lower_limit>
            <ci_upper_limit>11.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.8</ci_lower_limit>
            <ci_upper_limit>9.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>9.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.0</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>10.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.7</ci_lower_limit>
            <ci_upper_limit>12.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Total Cholesterol (TC)</title>
        <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the TC levels. The change from baseline at Week 12 was recorded.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg</title>
            <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0524B 2g/40mg</title>
            <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin 40 mg</title>
            <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>Atorvastatin 80 mg</title>
            <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Total Cholesterol (TC)</title>
          <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the TC levels. The change from baseline at Week 12 was recorded.</description>
          <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="361"/>
                <count group_id="O3" value="280"/>
                <count group_id="O4" value="402"/>
                <count group_id="O5" value="410"/>
                <count group_id="O6" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.1" lower_limit="-30.1" upper_limit="-26.2"/>
                    <measurement group_id="O2" value="-30.0" lower_limit="-31.5" upper_limit="-28.4"/>
                    <measurement group_id="O3" value="-24.6" lower_limit="-26.4" upper_limit="-22.7"/>
                    <measurement group_id="O4" value="-29.4" lower_limit="-30.9" upper_limit="-27.9"/>
                    <measurement group_id="O5" value="-34.2" lower_limit="-35.7" upper_limit="-32.7"/>
                    <measurement group_id="O6" value="-36.1" lower_limit="-37.6" upper_limit="-34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.595</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.2</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.1</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Lipoprotein (a) (Lp[a])</title>
        <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the Lp(a) levels. The change from baseline at Week 12 was recorded.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg</title>
            <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0524B 2g/40mg</title>
            <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin 40 mg</title>
            <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>Atorvastatin 80 mg</title>
            <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Lipoprotein (a) (Lp[a])</title>
          <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the Lp(a) levels. The change from baseline at Week 12 was recorded.</description>
          <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
          <units>Percentage change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="272"/>
                <count group_id="O4" value="396"/>
                <count group_id="O5" value="404"/>
                <count group_id="O6" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.2" lower_limit="-19.9" upper_limit="-10.6"/>
                    <measurement group_id="O2" value="-14.6" lower_limit="-17.9" upper_limit="-11.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-2.9" upper_limit="2.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-3.4" upper_limit="3.4"/>
                    <measurement group_id="O5" value="7.8" lower_limit="4.6" upper_limit="11.1"/>
                    <measurement group_id="O6" value="8.8" lower_limit="5.5" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-18.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.2</ci_lower_limit>
            <ci_upper_limit>-14.2</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate of the difference between treatments with a corresponding distribution-free CI based on Wilcoxonâs rank sum test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-20.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.0</ci_lower_limit>
            <ci_upper_limit>-16.6</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate of the difference between treatments with a corresponding distribution-free CI based on Wilcoxonâs rank sum test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-23.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.8</ci_lower_limit>
            <ci_upper_limit>-19.4</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate of the difference between treatments with a corresponding distribution-free CI based on Wilcoxonâs rank sum test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-24.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.6</ci_lower_limit>
            <ci_upper_limit>-20.0</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate of the difference between treatments with a corresponding distribution-free CI based on Wilcoxonâs rank sum test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in C-reactive Protein (CRP)</title>
        <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the CRP levels. The change from baseline at Week 12 was recorded.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg</title>
            <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0524B 2g/40mg</title>
            <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin 40 mg</title>
            <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>Atorvastatin 80 mg</title>
            <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in C-reactive Protein (CRP)</title>
          <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the CRP levels. The change from baseline at Week 12 was recorded.</description>
          <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
          <units>Percentage change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="274"/>
                <count group_id="O4" value="397"/>
                <count group_id="O5" value="406"/>
                <count group_id="O6" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.4" lower_limit="-23.8" upper_limit="-7.0"/>
                    <measurement group_id="O2" value="-20.0" lower_limit="-27.3" upper_limit="-12.7"/>
                    <measurement group_id="O3" value="-19.5" lower_limit="-26.2" upper_limit="-12.8"/>
                    <measurement group_id="O4" value="-28.6" lower_limit="-34.2" upper_limit="-22.9"/>
                    <measurement group_id="O5" value="-33.3" lower_limit="-38.0" upper_limit="-28.6"/>
                    <measurement group_id="O6" value="-38.1" lower_limit="-43.1" upper_limit="-33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.6</ci_lower_limit>
            <ci_upper_limit>7.5</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate of the difference between treatments with a corresponding distribution-free CI based on Wilcoxonâs rank sum test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>6.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>13.8</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate of the difference between treatments with a corresponding distribution-free CI based on Wilcoxonâs rank sum test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>11.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.2</ci_lower_limit>
            <ci_upper_limit>18.8</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate of the difference between treatments with a corresponding distribution-free CI based on Wilcoxonâs rank sum test</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Non-parametric ANOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>16.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.8</ci_lower_limit>
            <ci_upper_limit>22.8</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate of the difference between treatments with a corresponding distribution-free CI based on Wilcoxonâs rank sum test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in TC/HDL-C Ratio</title>
        <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the TC and HDL-C levels. The TC/HDL-C ratio was then calculated for baseline and Week 12 and the change from baseline at Week 12 was recorded.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg</title>
            <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0524B 2g/40mg</title>
            <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin 40 mg</title>
            <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>Atorvastatin 80 mg</title>
            <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in TC/HDL-C Ratio</title>
          <description>Blood samples taken at baseline and after 12 weeks of treatment to determine the TC and HDL-C levels. The TC/HDL-C ratio was then calculated for baseline and Week 12 and the change from baseline at Week 12 was recorded.</description>
          <population>All randomized participants who had taken at least 1 dose of post-randomization study medication and had a baseline value and at least one post-titration measurement for the endpoint.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="361"/>
                <count group_id="O3" value="280"/>
                <count group_id="O4" value="402"/>
                <count group_id="O5" value="410"/>
                <count group_id="O6" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.0" lower_limit="-43.2" upper_limit="-38.7"/>
                    <measurement group_id="O2" value="-42.3" lower_limit="-44.2" upper_limit="-40.5"/>
                    <measurement group_id="O3" value="-28.2" lower_limit="-30.4" upper_limit="-26.0"/>
                    <measurement group_id="O4" value="-31.5" lower_limit="-33.3" upper_limit="-29.8"/>
                    <measurement group_id="O5" value="-36.0" lower_limit="-37.7" upper_limit="-34.2"/>
                    <measurement group_id="O6" value="-36.7" lower_limit="-38.5" upper_limit="-35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-12.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.6</ci_lower_limit>
            <ci_upper_limit>-9.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-10.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.2</ci_lower_limit>
            <ci_upper_limit>-8.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-6.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>-4.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model with factors for baseline LDL-C and triglyceride stratum, gender, cohort of participants, treatment group and baseline parameter covariate</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-5.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>-3.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of &gt;=3 x Upper Limit of Normal (ULN)</title>
        <description>Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of either AST or ALT that were 3 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg and MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of &gt;=3 x Upper Limit of Normal (ULN)</title>
          <description>Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of either AST or ALT that were 3 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively.</description>
          <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="1577"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Proportion</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Elevations in ALT and/or AST of &gt;=5 x ULN</title>
        <description>Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of either AST or ALT that was 5 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg and MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevations in ALT and/or AST of &gt;=5 x ULN</title>
          <description>Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of either AST or ALT that was 5 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively.</description>
          <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="1577"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Proportion</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Elevations in ALT and/or AST of &gt;=10 x ULN</title>
        <description>Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of either AST or ALT that was 10 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevations in ALT and/or AST of &gt;=10 x ULN</title>
          <description>Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of either AST or ALT that was 10 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively.</description>
          <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="1577"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.346</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Proportion</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Creatine Kinase (CK) &gt;=10 x ULN</title>
        <description>Participants had CK assessed throughout the 12 week treatment period. Participants who had any CK level that was &gt;=10 x ULN were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Creatine Kinase (CK) &gt;=10 x ULN</title>
          <description>Participants had CK assessed throughout the 12 week treatment period. Participants who had any CK level that was &gt;=10 x ULN were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively.</description>
          <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="1577"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.556</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Proportion</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CK &gt;=10 x ULN With Muscle Symptoms</title>
        <description>Participants had CK assessed throughout the 24 week treatment period. Participants who had any CK level that was &gt;=10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CK &gt;=10 x ULN With Muscle Symptoms</title>
          <description>Participants had CK assessed throughout the 24 week treatment period. Participants who had any CK level that was &gt;=10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively.</description>
          <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="1577"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.134</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Proportion</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CK &gt;=10 x ULN With Muscle Symptoms - Drug Related</title>
        <description>Participants had CK assessed throughout the 12 week treatment period. Participants who had any CK level that was &gt;=10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly related to study drug were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CK &gt;=10 x ULN With Muscle Symptoms - Drug Related</title>
          <description>Participants had CK assessed throughout the 12 week treatment period. Participants who had any CK level that was &gt;=10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly related to study drug were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively.</description>
          <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="1577"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.134</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Proportion</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New Diagnosis of Impaired Fasting Blood Glucose</title>
        <description>Participants had blood glucose levels assessed throughout the 12 week treatment period. Participants who had the new diagnosis of impaired fasting blood glucose were recorded. A pre-defined set of MedDRA terms was used to identify participants whose glycemic status became âimpairedâ during the course of treatment (from clinical adverse experience reports). The MedDRA terms were as follows: blood glucose increased, blood glucose abnormal, glucose tolerance decreased, glucose tolerance test abnormal, carbohydrate tolerance decreased, glucose tolerance impaired, hyperglycaemia, impaired fasting glucose, impaired insulin secretion, metabolic syndrome, insulin resistance, insulin resistance syndrome.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication and normal glycemic status at baseline. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Diagnosis of Impaired Fasting Blood Glucose</title>
          <description>Participants had blood glucose levels assessed throughout the 12 week treatment period. Participants who had the new diagnosis of impaired fasting blood glucose were recorded. A pre-defined set of MedDRA terms was used to identify participants whose glycemic status became âimpairedâ during the course of treatment (from clinical adverse experience reports). The MedDRA terms were as follows: blood glucose increased, blood glucose abnormal, glucose tolerance decreased, glucose tolerance test abnormal, carbohydrate tolerance decreased, glucose tolerance impaired, hyperglycaemia, impaired fasting glucose, impaired insulin secretion, metabolic syndrome, insulin resistance, insulin resistance syndrome.</description>
          <population>All participants who had taken at least 1 dose of study medication and normal glycemic status at baseline. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="1343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5625</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New Diagnosis of Diabetes</title>
        <description>Participants had blood glucose levels assessed throughout the 12 week treatment period. Participants who with newly diagnosed of diabetes were recorded. A participant was classified as having new onset diabetes if they experienced an adverse Event (AE) related to a diagnosis of diabetes (based on a pre-defined set of Medical Dictionary for Regulatory Activities [MedDRA] terms), or if they started taking an anti-diabetic medication during the course of the study. The MedDRA terms were as follows: diabetes mellitus, diabetes mellitus insulin-dependent, diabetes mellitus non-insulin dependent, insulin-requiring type II diabetes mellitus, insulin resistant diabetes, diabetes with hyperosmolarity, latent autoimmune diabetes in adults.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication and did not have diabetes at baseline. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Diagnosis of Diabetes</title>
          <description>Participants had blood glucose levels assessed throughout the 12 week treatment period. Participants who with newly diagnosed of diabetes were recorded. A participant was classified as having new onset diabetes if they experienced an adverse Event (AE) related to a diagnosis of diabetes (based on a pre-defined set of Medical Dictionary for Regulatory Activities [MedDRA] terms), or if they started taking an anti-diabetic medication during the course of the study. The MedDRA terms were as follows: diabetes mellitus, diabetes mellitus insulin-dependent, diabetes mellitus non-insulin dependent, insulin-requiring type II diabetes mellitus, insulin resistant diabetes, diabetes with hyperosmolarity, latent autoimmune diabetes in adults.</description>
          <population>All participants who had taken at least 1 dose of study medication and did not have diabetes at baseline. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="703"/>
                <count group_id="O2" value="1523"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0233</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Confirmed Adjudicated Cardiovascular Event</title>
        <description>Select serious adverse cardiovascular events and all-cause mortality that occurred during the treatment phase of the study were adjudicated by an expert committee external to the sponsor. Those events confirmed by the committee a cardiovascular events were recorded.</description>
        <time_frame>up to 14 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Confirmed Adjudicated Cardiovascular Event</title>
          <description>Select serious adverse cardiovascular events and all-cause mortality that occurred during the treatment phase of the study were adjudicated by an expert committee external to the sponsor. Those events confirmed by the committee a cardiovascular events were recorded.</description>
          <population>All participants who had taken at least 1 dose of study medication. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="1607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7858</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experience at Least 1 Clinical Adverse Event (AE)</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant.</description>
        <time_frame>up to 14 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience at Least 1 Clinical Adverse Event (AE)</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant.</description>
          <population>All participants who had taken at least 1 dose of study medication. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="1607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6"/>
                    <measurement group_id="O2" value="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>13.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.4</ci_lower_limit>
            <ci_upper_limit>18.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experience at Least 1 Laboratory Adverse Event (AE)</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.</description>
        <time_frame>up to 14 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience at Least 1 Laboratory Adverse Event (AE)</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.</description>
          <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="1607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Discontinued From the Study Due to a Clinical AE</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant. Participants who were discontinued from the study due to a clinical AE were recorded.</description>
        <time_frame>up to 14 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Discontinued From the Study Due to a Clinical AE</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant. Participants who were discontinued from the study due to a clinical AE were recorded.</description>
          <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="1607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>11.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.9</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Discontinued From the Study Due to a Laboratory AE</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. Participants who were discontinued from the study due to a laboratory AE were recorded.</description>
        <time_frame>up to 14 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Discontinued From the Study Due to a Laboratory AE</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. Participants who were discontinued from the study due to a laboratory AE were recorded.</description>
          <population>All participants who had taken at least 1 dose of study medication and had data available for endpoint. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="1607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experience at Least 1 Hepatitis-related Clinical AE</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Hepatitis-related AEs were identified by a collective review using the following pre-specified set of preferred terms: cholestasis, hepatic necrosis, hepatocellular damage, cytolytic hepatitis, hepatitis, hepatomegaly, jaundice, hepatic failure, hepatitis cholestatic, jaundice cholestatic, hepatitis fulminant, hyperbilirubinaemia, jaundice hepatocellular, ocular icterus, yellow skin, hepatic function abnormal, acute hepatic failure, subacute hepatic failure, hepatitis acute, hepatitis toxic, hepatotoxicity, and mixed hepatocellular-cholestatic injury.</description>
        <time_frame>up to 14 weeks</time_frame>
        <population>All participants who had taken at least 1 dose of study medication. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)</title>
            <description>Participants who received either MK-0524B 2g/20mg or MK-0524B 2g/40mg (pooled)</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10, 20, 40, or 80 mg (Pooled)</title>
            <description>Participants who received either atorvastatin 10, 20, 40 or 80 mg (pooled)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience at Least 1 Hepatitis-related Clinical AE</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Hepatitis-related AEs were identified by a collective review using the following pre-specified set of preferred terms: cholestasis, hepatic necrosis, hepatocellular damage, cytolytic hepatitis, hepatitis, hepatomegaly, jaundice, hepatic failure, hepatitis cholestatic, jaundice cholestatic, hepatitis fulminant, hyperbilirubinaemia, jaundice hepatocellular, ocular icterus, yellow skin, hepatic function abnormal, acute hepatic failure, subacute hepatic failure, hepatitis acute, hepatitis toxic, hepatotoxicity, and mixed hepatocellular-cholestatic injury.</description>
          <population>All participants who had taken at least 1 dose of study medication. Results for participants who received either MK-0524B 2g/20mg or 2g/40 mg were pooled. Results for participants who received atorvastatin 10, 20, 40, or 80 mg were pooled.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="1607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4997</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 14 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MK-0524B 2g/20 mg</title>
          <description>Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>MK-0524B 2g/40 mg</title>
          <description>Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Atorvastatin 10 mg</title>
          <description>Atorvastatin 10 mg, orally, once daily for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Atorvastatin 20 mg</title>
          <description>Atorvastatin 20 mg, orally, once daily for 12 weeks</description>
        </group>
        <group group_id="E5">
          <title>Atorvastatin 40 mg</title>
          <description>Atorvastatin 40 mg, orally, once daily for 12 weeks</description>
        </group>
        <group group_id="E6">
          <title>Atorvastatin 80 mg</title>
          <description>Atorvastatin 80 mg, orally, once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="439"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="437"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="433"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="298"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="439"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="437"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="435"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="298"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="439"/>
                <counts group_id="E5" events="19" subjects_affected="18" subjects_at_risk="437"/>
                <counts group_id="E6" events="18" subjects_affected="15" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="435"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="298"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="67" subjects_affected="57" subjects_at_risk="297"/>
                <counts group_id="E2" events="120" subjects_affected="102" subjects_at_risk="435"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="298"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="439"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="437"/>
                <counts group_id="E6" events="20" subjects_affected="19" subjects_at_risk="433"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

